BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34913341)

  • 1. In Silico-Based Experiments on Mechanistic Interactions between Several Intestinal Permeation Enhancers with a Lipid Bilayer Model.
    Kneiszl R; Hossain S; Larsson P
    Mol Pharm; 2022 Jan; 19(1):124-137. PubMed ID: 34913341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of Bile Composition on Membrane Incorporation of Transient Permeability Enhancers.
    Hossain S; Joyce P; Parrow A; Jõemetsa S; Höök F; Larsson P; Bergström CAS
    Mol Pharm; 2020 Nov; 17(11):4226-4240. PubMed ID: 32960068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the physicochemical interactions between exenatide and two intestinal permeation enhancers: Sodium caprate (C
    Twarog C; Fattal E; Noiray M; Illel B; Brayden DJ; Taverna M; Hillaireau H
    Int J Pharm; 2022 Oct; 626():122131. PubMed ID: 36028084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction between Permeation Enhancers and Lipid Bilayers.
    Kang C; Bernaldez M; Stamatis SD; Rose JP; Sun R
    J Phys Chem B; 2024 Feb; 128(7):1668-1679. PubMed ID: 38232311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A head-to-head Caco-2 assay comparison of the mechanisms of action of the intestinal permeation enhancers: SNAC and sodium caprate (C
    Twarog C; Liu K; O'Brien PJ; Dawson KA; Fattal E; Illel B; Brayden DJ
    Eur J Pharm Biopharm; 2020 Jul; 152():95-107. PubMed ID: 32387703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal Permeation Enhancers Beyond Sodium Caprate and SNAC - What is Coming Next?
    Bohley M; Leroux JC
    Adv Sci (Weinh); 2024 Jun; ():e2400843. PubMed ID: 38884149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety concerns over the use of intestinal permeation enhancers: A mini-review.
    McCartney F; Gleeson JP; Brayden DJ
    Tissue Barriers; 2016; 4(2):e1176822. PubMed ID: 27358756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of colonic drug absorption by the transcellular permeation route.
    Tomita M; Hayashi M; Horie T; Ishizawa T; Awazu S
    Pharm Res; 1988 Dec; 5(12):786-9. PubMed ID: 3247289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absorption enhancement, mechanistic and toxicity studies of medium chain fatty acids, cyclodextrins and bile salts as peroral absorption enhancers.
    Sharma P; Varma MV; Chawla HP; Panchagnula R
    Farmaco; 2005; 60(11-12):884-93. PubMed ID: 16226752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of the intestinal permeation enhancers, SNAC and sodium caprate (C
    Twarog C; McCartney F; Harrison SM; Illel B; Fattal E; Brayden DJ
    Eur J Pharm Sci; 2021 Mar; 158():105685. PubMed ID: 33359131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Sodium
    Li Y; Yang D; Zhu C
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30453465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C
    Twarog C; Fattah S; Heade J; Maher S; Fattal E; Brayden DJ
    Pharmaceutics; 2019 Feb; 11(2):. PubMed ID: 30781867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revealing the interaction between peptide drugs and permeation enhancers in the presence of intestinal bile salts.
    Hossain S; Kneiszl R; Larsson P
    Nanoscale; 2023 Dec; 15(47):19180-19195. PubMed ID: 37982184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrointestinal Permeation Enhancers for the Development of Oral Peptide Pharmaceuticals.
    Kim JC; Park EJ; Na DH
    Pharmaceuticals (Basel); 2022 Dec; 15(12):. PubMed ID: 36559036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Labrasol
    Heade J; Maher S; Bleiel SB; Brayden DJ
    J Pharm Sci; 2018 Jun; 107(6):1648-1655. PubMed ID: 29462634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions of oral permeation enhancers with lipid membranes in simulated intestinal environments.
    Larsen NW; Kostrikov S; Hansen MB; Hjørringgaard CU; Larsen NB; Andresen TL; Kristensen K
    Int J Pharm; 2024 Apr; 654():123957. PubMed ID: 38430950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation strategies to improve the efficacy of intestinal permeation enhancers
    Maher S; Brayden DJ
    Adv Drug Deliv Rev; 2021 Oct; 177():113925. PubMed ID: 34418495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salcaprozate sodium (SNAC) enhances permeability of octreotide across isolated rat and human intestinal epithelial mucosae in Ussing chambers.
    Fattah S; Ismaiel M; Murphy B; Rulikowska A; Frias JM; Winter DC; Brayden DJ
    Eur J Pharm Sci; 2020 Nov; 154():105509. PubMed ID: 32777258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a Non-Aqueous Dispersion to Improve Intestinal Epithelial Flux of Poorly Permeable Macromolecules.
    Maher S; Medani M; Carballeira NN; Winter DC; Baird AW; Brayden DJ
    AAPS J; 2017 Jan; 19(1):244-253. PubMed ID: 27739012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physical and barrier changes in gastrointestinal mucus induced by the permeation enhancer sodium 8-[(2-hydroxybenzoyl)amino]octanoate (SNAC).
    Mortensen JS; Bohr SS; Harloff-Helleberg S; Hatzakis NS; Saaby L; Nielsen HM
    J Control Release; 2022 Dec; 352():163-178. PubMed ID: 36314534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.